AstraZeneca's Farxiga Doesn't Show Statistical Significance in Covid-19 Trial
April 12 2021 - 2:48AM
Dow Jones News
By Adria Calatayud
AstraZeneca PLC said Monday that a Phase 3 trial to assess the
potential of its Farxiga diabetes drug to treat patients with
Covid-19 at risk of developing serious complications didn't achieve
statistical significance for its primary target.
The trial didn't achieve statistical significance for the
primary endpoint of prevention, measuring organ dysfunction and
all-cause mortality, and of recovery, measuring a change in
clinical status from early recovery to death, at 30 days, the
British pharmaceutical giant said.
The full trial results will be presented at the American College
of Cardiology Scientific Sessions in May, AstraZeneca said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
April 12, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
